Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017636 (glioblastoma)
 18,345 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Extraneural metastases from malignant glioma and glioblastoma are believed to be rare. The most common sites of metastases are lung, lymph nodes, bone, and liver. We recently encountered two patients with glioblastoma multiforme who presented with pain and thrombocytopenia caused by diffuse metastasis to bone marrow. A premortem diagnosis was established in the first patient with the aid of peroxidase-antiperoxidase staining of the bone marrow biopsy specimen for glial fibrillary acidic protein, a glial-specific marker. In the second patient glial fibrillary acidic protein staining confirmed the glial nature of the primary brain tumor as well as the metastatic tumor in bone marrow. The first patient also had metastatic nodules on the pleural surface and on the fifth rib. All three metastatic foci had similar cellular morphology, suggesting selection of a population of tumor cells with extraneural metastatic potential.
 ...
PMID:Diffuse bone marrow metastasis by glioblastoma: premortem diagnosis by peroxidase-antiperoxidase staining for glial fibrillary acidic protein. 631 36

Clinical and pathomorphological findings in 2 stillborn and 15 lifeborn children with primary intracranial tumors are reported. All infants died within the first year of life and the tumors were confirmed histologically. In 6 children the tumors (3 intracranial teratomas, 1 glioblastoma, 1 hemangioblastoma, 1 choroid plexus papilloma) were present at birth. All 6 were born with pathologically enlarged heads. Another child exhibited symptoms of brain tumor at the age of three weeks. The tumor was probably present at birth as well. In the remaining infants the signs and symptoms of tumor development became evident some months after birth. These tumors might have occurred postnatally. In a girl aged 9 months, a nephroblastoma of the right kidney and a malignant cerebral tumor, probably a glioma, were present. An incidental coexistence of both tumors is considered, however, a common etiology cannot be excluded. 8 of the 17 intracranial tumors were supratentorially situated. This supports the view that the proportion of supratentorial tumors is higher in early life than in older children.
 ...
PMID:[Primary intracranial tumors as cause of death in the fetus and infant]. 632 94

A pharmacokinetic two-compartment model for the treatment of brain tumors in man was simulated with the aid of a computer. The parameters necessary for the simulations such as inactivation rate constant, elimination rate constant, distribution volume, blood volume, cerebral blood flow, and cytotoxic drug concentration were either determined in this study or obtained from the literature. A proteinaceous antitumor antibiotic, neocarzinostatin (NCS), was utilized as a prototype drug because it has features making it advantageous in the treatment of brain tumor. In particular, NCS has an extremely short half-life in serum (t 1/2 less than or equal to 3 s), while it is relatively stable in the cerebrospinal fluid (CSF) (t 1/2 approximately 50 s). Therefore, the drug level in the cerebral compartment can be made adequately high with an appropriate infusion velocity into the cerebral compartment; however, it was possible to keep the plasma level of the drug much lower than the toxic level. Thus, few side-effects should result. In an in vitro study, NCS was found to exhibit its cytotoxicity to glioblastoma cells at a concentration as low as 0.005 microgram/ml. In contrast, the cytotoxicity was not apparent for the normal glia cells at 0.1 microgram/ml. The model being considered in this investigation is a two-compartment model, which consists of the cerebral compartment and the rest of the circulatory system of the body. In this case the drug is infused via an internal carotid artery. The results of pharmacokinetic simulation and dose regimens for NCs are presented, based on the effective concentration of the drug to glioblastoma cells in culture and the available pharmacological parameters.
 ...
PMID:A pharmacokinetic simulation model for chemotherapy of brain tumor with an antitumor protein antibiotic, neocarzinostatin. Theoretical considerations behind a two-compartment model for continuous infusion via an internal carotid artery. 645 12

Seventeen patients, aged 9 to 63 years (mean age 38.2 years), with 6 recurring malignant glioma, 5 malignant meningioma, 4 metastatic brain tumor, one endodermal sinus tumor and one embryonal carcinoma were postoperatively treated with adriamycin (ADM). As a rule, 20 mg of ADM (to 960 mg in a total dosis) were given by means of intra-carotid administration every two weeks (to 250 months in duration). According to Karnofsky's evaluation, 4 of 6 glioblastoma patients(66.7%), 4 of 5 malignant meningioma (80%), 2 of 4 metastatic brain tumor (50%) and one embryonal carcinoma had improvement of clinical condition, at least during two months after the beginning of the treatment, and/or remission of more than 50% of the enhanced area on CT scan. Consequently, allover response rate was 64.7%. Tumor tissue concentration of ADM administered intraoperatively by the same regimen, was estimated by fluorescence assay, twenty times in sixteen patients. The level of the concentration was higher in malignant tumor (3.6 to 6.2 micrograms/g) than in low grade astrocytoma (1.5 microgram/g in maximum) during sixty minutes after ADM administration. On the other hand, when ADM of same dosis was given intravenously, maximum serum level was 2.8 microgram/ml, which was less than half in comparison with tissue level of intracarotid administration. There was a serious myelosuppression in two cases in our series, but no cardiomuscular damage was observed in any cases. In conclusion, ADM concentration of brain tissue such as malignant meningioma, metastatic brain tumor and, even glioblastoma, was highly obtained. Further, intermittent intra-carotid administration of ADM was more effective than intravenous dripping in treating malignant intracranial tumor, although side effects should be carefully avoided.
 ...
PMID:[Postoperative treatment for malignant intracranial tumors--especially concerning intermittent intra-carotid administration of adriamycin]. 646 30

In recent years, considerable interest has been directed towards the role of neurotransmitters in various types of brain dysfunctions. There are increasing experimental and clinical evidences that disturbances in the metabolism of central monoamine play an important role in the pathogenesis of brain diseases. Brain tumors are thought to affect and change the neurotransmitter function of the surrounding cerebral tissues. In this study, we tried to analyze and accumulate data about tissue concentrations of biogenic amines in brain tumors and their distribution. Samples from thirty-four intracranial tumors removed at operations were studied. The concentrations in tumor tissues were measured by high performance liquid chromatography systems which were equipped with electrochemical detection (LCEC) and were particularly well suited for the separation and the measurement of the concentration of norepinephrine (NE), dopamine (DA), 5-hydroxytryptamine (5-HT), and their metabolites; homovanillic acid (HVA), 5-hydroxyindolacetic acid (5-HIAA) and 3-methyoxy-4-hydroxyphenylethyleneglycol (MHPG) in brain tissues. NE levels were under 3ng/g in twenty-five of thirty cases. DA levels were not detected in more than half of the cases. 5-HT levels varied from 0 ng/g to 166.4 ng/g. HVA levels were detected in one glioblastoma, one metastatic tumor, one meningioma and one hemangioblastoma. 5HIAA levels were not detected in most cases except for two meningiomas and one malignant lymphoma. Distribution of tissue concentrations of biogenic amines and their metabolites in four demarcated brain tumors was studied. Samples for determination of tissue concentrations were taken from tumor tissue at central, middle, and peripheral or adjacent portion from the edge of tumor.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Tissue concentrations of biogenic amines in brain tumors and their distribution]. 648 88

Brain tumors in infants and children are different from those in adults in type and location of tumor as well as accompanying complications. Given this fact, and the fact that these patients are under development, careful consideration is required for determination of treatment planning. Thus, we have investigated the curative results of brain tumors in infants and children and factors affecting prognosis. In this study, astrocytoma which is most frequently seen in infants and children was analyzed in 181 patients. One hundred forty three of them were diagnosed as benign astrocytoma; and the other 38, as malignant astrocytoma or glioblastoma. In respect of location, supratentorial tumors were seen in 73 patients, while subtentorial tumors occurred in 61; nine tumors infiltrated into both regions. The 5-year survival rate of benign astrocytoma was 50%, compared with 6.3% in malignant astrocytoma. As for relations to location of tumor, 66% of tumors which infiltrated into the supratentorial and subtentorial regions were malignant, and the prognosis was poor: the 5-year survival rate was 14.2%. The 5 year survival rate of subtentorial tumors was 38.9%, whereas that of supratentorial tumors was 57.6%. Analysis by age revealed that malignancy increased in proportion to age over 12 months after birth; between the ages of one and six years, the incidence of malignant tumors was 9% and the 5-year survival rate was 48%, while between the ages of 12 and 16, the rates were 29% and 14%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Brain tumors in infants and children--factors affecting prognosis. (2) Location and prognosis of astrocytoma]. 664 37

The permeability of different brain tumor models to horseradish peroxidase (HRP) was examined by determining the fraction of tumor that contained HRP after intravenous administration. The intracerebral tumor models studied were Avian Sarcoma Virus (ASV)-induced tumors and tumors from transplanted RG-2, S69-C1-5, and 9L cell lines. The average fraction of RG-2 tumors permeable to HRP was .95; of S69-C1-5 tumors, .699; of ASV-induced tumors. .63; and of 9L tumors, .52. Except for the RG-2 tumors, there was considerable regional variation in HRP permeability, which was most marked in the ASV-induced tumors. In ASV-induced tumors, HRP permeability did not correlate with tumor histological classification, size, or anatomic location within the brain. The subcutaneous tumor models studied were RG-2-, S69-C1-5, and 9L-transplanted tumors in rats, and human glioblastoma cell lines transplanted into nude mice. All were completely permeable to HRP. These results indicate that significant differences in permeability to HRP exist among brain tumor models when the tumors are intracerebral, and that all subcutaneous tumors from transplanted glial cell lines are completely permeable to HRP. These variables must be considered in future studies of permeability in experimental brain tumors. Care must be exercised in extrapolating results about permeability from one brain tumor model to another.
 ...
PMID:Permeability of different experimental brain tumor models to horseradish peroxidase. 706 86

Interferon inducing activity, antitumor activity and toxicity of poly ICLC (poly IC stabilized with poly L-Lysine and carboxymethyl cellulose) in rodents were studied. SD strain rats were injected intravenously with poly IC or poly ICLC. Interferon in rat plasma was assayed by a plaque reduction method using stomatitis virus. The peak level of plasma interferon of the poly ICLC injection rat was as high as that of poly IC injection rat, and in the former, high level of plasma interferon persisted for 4-12 hours. Next, brain tumor-bearing rats were treated intravenously with poly ICLC and observed for death daily. Weekly treatment with 1 mg/kg of poly ICLC increased the mean survival time although no antitumor effect was observed with poly IC. The LD 50 value of poly IC was 33.5 mg/kg, and that of poly ICLC was 18.6 mg/kg and as to poly ICLC administration, no remarkable side effect was recognized below the dose of 1.5 mg/kg. In clinical trials, poly ICLC was given intravenously at the dose of 0.05-0.2 mg/kg to 9 patients with malignant brain tumor. (6 patients were glioblastoma, 1 was astrocytoma, and 2 were ependymoma.) In 2 patients, poly ICLC was administered once, in 2 patients twice, in 2 patients 3 times, and in 3 patients more than 5 times. The interval of each administration was 7 days. Poly ICLC induced high level of serum interferon (more than 100 reference unit/ml) in all patients and over 100 unit/ml of interferon was maintained for 24 hours. The highest interferon titer induced was 875 unit/ml. The most frequently encountered toxic reaction was fever, which occurred in all cases. The mean peak temperature elevation was 1.9 degrees C, which usually occurred 4-8 hours after drug administration. Modest hypotention was detected in one case. Leucopenia was detected in 3 cases. These abnormalities were all modest, and improved in a few days. As to the effect of poly ICLC, neurological improvement was recognized in 3 cases, and in one of them, remission on CT scan was also recognized.
 ...
PMID:[Effect of interferon inducer (poly ICLC) in the treatment of malignant brain tumor (author's transl)]. 709 65

The prognosis, site of occurrence, and histologic type of primary brain tumors are age-dependent phenomena. In general, the incidence of meningiomas, acoustic Schwannomas, and glioblastomas increases with advancing age until the end of the eighth decade. Of 99 patients consecutively admitted to an aggressive multimodality treatment program for glioblastoma multiforme, 18 per cent were in the 61-70 age group and 4 per cent in the 71-80 group; the oldest was 85. The operative mortality was only 4 per cent. In 16 patients over 65, the 6- and 12-month calculated survival probabilities were 0.65 and 0.31, respectively. The Kaplan-Meier survival curve for these patients was significantly different from that for 26 patients under the age of 40. Grade 4 astrocytomas were present in 62 per cent of patients under 40 but in 83 per cent of patients over 61. In all glioblastoma populations, age is the most significant prognostic variable. The incidence of metastic brain tumors also increases with age, and all of the usual primary sites are represented. The prognosis for elderly patients with metastatic brain tumor is uniformly worse than that for younger patients, even though modern diagnostic and operative techniques carry virtually the same morbidity and mortality rates in older patients as in younger ones. It is vitally important, therefore, that the clinical effects of treatable intracranial tumors in the elderly are not ascribed to dementia, the aging process, the systemic effects of cancer, or the side effects of cancer therapy, without suitable diagnostic investigation.
 ...
PMID:Brain tumors and the geriatric patient. 709 52

Eighty three patients suffering from brain tumors have been treated by anticancer pellets containing 5-FU, urokinase, mitomycin and BUdR in dimethylsiloxan (Silastic) for three years. Constant and prolonged release of the chemicals from the anticancer pellet had already been proved in vitro. The amount of daily release were 1-3/1,000 of original volume. Tissue concentration of 5-FU was measured by bioassay system using staphylococcus 209 P strain with plate dilution method. In spite of the rapid disappearance of serum 5-FU, the local high accumulation of 5-FU was demonstrated in vivo. In rat neurogenic tumor, 1.104 microgram/g was detected on 60 days after the application of anticancer pellet containing 500 mg of 5-FU. The growth of tumor was also suppressed. The clinical study consists of 83 patients, 30 of glioblastoma, 19 of metastatic brain tumor, 13 of astrocytoma, 7 of oligodendroglioma, 4 of ependymoblastoma, 4 of malignant lymphoma and 6 of others. The median survival time of gliblastoma was prolonged to 71.5 weeks by the implantation of anticancer pellet from 40 weeks of control group. However, the median survival time of astrocytoma and metastatic brain tumor were 24 and 6 months, respectively, which have no significant difference from control groups. In the patients of metastatic brain tumor, the regrowth of metastatic foci in the brain was completely suppressed. However, most of them were succumbed from the original tumors. The concentration of 5-FU in several human tissue was measured in ten patients with different time intervals after the implantation of the anticancer pellet. Although they have different histologic patterns, the concentrations of 5-FU in human brain tumors were ranged from 0.05 to 0.67 microgram/g by 14 months after the implantation of the anticancer pellet. The adjacent cystic fluids also contain from 0.62 to 4.9 microgram/ml of 5-FU for two years. These results mean that they are keeping higher level of 5-FU than the tumoricidal level of 5-FU (0.056 microgram/g) for more than two years. On the other hand, no respective accumulation was demonstrated in other tissues. None of the patients showed any adverse reactions except a continuous slight fever up to 38 degrees C.
 ...
PMID:[Treatment of brain tumors with anticancer pellet--experimental and clinical study (author's transl)]. 709 76


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>